[1] | Farrell GC, larter CZ. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43: S99–112. |
[2] | Marchesini G, Moscatiello S, Di Domizio S, Forlani G. 2008. Obesity-associated liver disease. J Clin Endocrinol Metab. 93: S74–80. |
[3] | Shoelson SE, Lee J, Goldfine AB. 2006. Inflammation and insulin resistance. J Clin Invest.116: 1793–801. |
[4] | Day CP, James OF. 1998. Steatohepatitis: a tale of “two hits”. Gastroenterology. 114: 842–5. |
[5] | Kahn BB, Flier JS.2000. Obesity and insulin resistance. J Clin Invest.106:473–81. |
[6] | Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 115: 1343–51. |
[7] | Ong JP, Younossi ZM. 2007. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 11: 1–16. |
[8] | Angulo P., Alba L.M., Petrovic L.M., Adams L.A., Lindor K.D., Jensen M.D. 2004. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J. Hepatol. 41: 943–949. |
[9] | Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J.2004. Beyond insulin resistance in NASH: TNF-alpha or adiponectin. Hepatology. 40: 46-54. |
[10] | Bugianesi E, Pagotto U, Manini R. 2005. Plasma adiponectin in nonalcoholic fatty liver disease is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 90:3498–504. |
[11] | Tokushige K., Takakura M., Tsuchiya-Matsushita N., Taniai M., Hashimoto E., Shiratori K.: 2007. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol.46: 1104–1110. |
[12] | Fan JG. 2008. of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis. 9: 63-7. |
[13] | Shetty S, Kusminski CM, Scherer PE. 2009. Adiponectin in health anddisease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci. 30: 234-9. |
[14] | Fabbrini E, Sullivan S, Klein S. 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 51: 679-89. |
[15] | H. Malhi, G.J. Gores. 2008. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease, Semin. Liver Dis. 28 (2008) 360–369. |
[16] | P. Puri, R.A. Baillie, M.M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, C. et al. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients withnonalcoholic fatty liver disease, J. Clin. Invest. 115; 1343–1351. |
[17] | M. Lazo, J.M. Clark. 2008. The epidemiology of nonalcoholic fatty liver disease: a global perspective, Semin. Liver Dis. 28: 339–350. |
[18] | Leon A, Paul A, Keith L. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905. |
[19] | Leon A, Keith L. 2007. Nonalcoholic fatty liver disease. Ann Epidemiol. 17: 863–869. |
[20] | Marcin K, Leonilde B, Piero P. 2010. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology. 24: 695–708. |
[21] | Ramon B, Krista R, José A, Fabio M. 2011. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Practice & Research Clinical Gastroenterology. 25: 231–44. |
[22] | Chan D, Vogel H. 2010. Current understanding of fatty acid biosynthesis and the acyl carrier protein. Biochem. J. 430: 1-19. |
[23] | Nguyen P, Leray V, Diez M, Serisier S, Le Bloc'h J, Siliart B, et al. 2008. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl). 92: 272-83. |
[24] | Ziemke F, Mantzoros CS. 2010. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 91: 258S–61S. |
[25] | Liu M, Liu F. 2009. Transcriptional and post-translational regulation of adiponectin. Biochem J. 425: 41–52. |
[26] | Kiess W, Petzold S, Topfer M. 2008. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab. 22: 135–53. |
[27] | Guerre-Millo M. Adiponectin: an update. 2008. Diabetes Metab. 34: 12–8. |
[28] | Aristeidis V, Kyriakoula M, Constantinos C, Michael K. 2012. The role of adiponectin in human vascular physiology. International Journal of Cardiology. 155: 188–193. |
[29] | Tilg H and Moschen AR. 2006. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 6: 772–83. |
[30] | Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al.2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis & Vascular Biology. 20:1595-9. |
[31] | Matsuzawa Y. 2010. Adiponectin: a key player in obesity relateddisorders. Curr Pharm Des. 16 : 1896-901. |
[32] | Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 112: 91–100. |